Candel Therapeutics, Inc. (NASDAQ: CADL) announced extended follow-up data from its phase 3 trial of aglatimagene besadenovec in localized prostate ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE